In summary, our study has shown in a diverse cohort of US adults that despite recent guidelines for SGLT2-is or GLP-1 RAs use in higher risk people with DM, few are actually taking them, and use is lower among the underserved. Here, GLP1R is linked to diabetes mellitus.